47,399 - 47,399
Pain 336,841 40,734 377,575
TREANDA 38,932 - 38,932
Other 14,259 70,837 85,096
Oncology 53,191 70,837 124,028
Other 37,995 117,517 155,512
$1,124,418 $284,185 $1,408,603
Nine Months Ended
September 30,
2007
United
States Europe Total
Sales:
PROVIGIL $593,394 $39,171 632,565
GABITRIL 39,814 6,268 46,082
CNS 633,208 45,439 678,647
ACTIQ 157,097 28,638 185,735
Generic OTFC 97,562 - 97,562
FENTORA 101,224 - 101,224
AMRIX - - -
Pain 355,883 28,638 384,521
TREANDA - - -
Other 13,044 56,645 69,689
Oncology 13,044 56,645 69,689
Other 40,823 114,122 154,945
$1,042,958 $244,844 $1,287,802
%
'/>"/>
SOURCE Cephalon, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Related biology technology :1.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain2.
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant3.
Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA4.
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia5.
Cephalon Quarterly Conference Call Invitation6.
Cephalon Announces Strong Third Quarter Financial Results7.
Cephalon Submits Supplemental New Drug Application for FENTORA8.
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma9.
Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available10.
Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain11.
Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application